Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Non-Current Assets: 2011-2024

Historic Non-Current Assets for Capricor Therapeutics (CAPR) over the last 14 years, with Dec 2024 value amounting to $7.1 million.

  • Capricor Therapeutics' Non-Current Assets rose 257.54% to $25.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.5 million, marking a year-over-year increase of 257.54%. This contributed to the annual value of $7.1 million for FY2024, which is 9.94% down from last year.
  • Capricor Therapeutics' Non-Current Assets amounted to $7.1 million in FY2024, which was down 9.94% from $7.9 million recorded in FY2023.
  • Capricor Therapeutics' 5-year Non-Current Assets high stood at $7.9 million for FY2023, and its period low was $941,713 during FY2020.
  • Moreover, its 3-year median value for Non-Current Assets was $7.2 million (2022), whereas its average is $7.4 million.
  • Per our database at Business Quant, Capricor Therapeutics' Non-Current Assets soared by 419.62% in 2021 and then declined by 9.94% in 2024.
  • Yearly analysis of 5 years shows Capricor Therapeutics' Non-Current Assets stood at $941,713 in 2020, then soared by 419.62% to $4.9 million in 2021, then spiked by 47.26% to $7.2 million in 2022, then increased by 9.33% to $7.9 million in 2023, then decreased by 9.94% to $7.1 million in 2024.